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LETTER TO THE EDITOR
Role of thrombin in mesangial proliferative glomerulonephritis
To the Editor: Thrombin, besides playing a central role in
blood clotting, activates its receptors by enzymatic cleavage
and is believed to be involved in various diseases through
receptor-mediated mitotic activity [1] on various cells in-
cluding mesangial cells [2]. In certain renal diseases, mes-
angial cell proliferation decreases glomerular filtration area
and impairs renal function. In glomerulonephritis, proco-
agulant activity is increased in the lesion [3], and thus
thrombin should be generated there. Anti-coagulation
therapy has been used in glomerulonephritis without any
markers to predict its effectiveness, which makes evaluation
of the therapy difficult. Thrombin is rapidly inactivated in
blood by endogenous inhibitors including antithrombin.
However, when thrombin is generated in the glomerulus,
some might escape from inactivation and appear in the
urine.
We examined urinary thrombin activity in glomerulone-
phritis to determine whether or not thrombin is involved in
mesangial proliferation in vivo. Nine patients with moder-
ate to severe mesangial proliferative glomerulonephritis (3
males, 6 females, 47.0 6 16.9 years), ten patients with
non-proliferative glomerulonephritis (3 minimal change
nephrotic syndrome, 7 membranous nephropathy; 5 males,
5 females; aged 58.9 6 13.8 years), and eleven healthy
volunteers (6 males, 5 females; aged 48.4 6 19.2 years)
were studied. Their serum creatinine level was , 2.0 mg/ml.
Fresh urine samples were collected within two hours after
the last voiding, centrifuged at 2,000 g for 30 minutes at 4°C
and supernatants were kept at 280°C until use. Butyloxy-
carbonyl-valyl-prolyl-arginine-methyl-coumaryl-amide was
used as a specific substrate, and linearly increasing fluores-
cence was measured spectroscopically. After a measure-
ment at five minutes, an excess of hirudin was added and
the measurement was continued for another five minutes.
Amidolytic activity of thrombin was calculated from the
difference between the two measurements. The values were
normalized by dividing by the concentration of urine cre-
atinine. Detection limit of the assay was 0.1 mU/ml of
thrombin.
Urinary thrombin activity was not detected in healthy
controls and was negligible (0.244 6 0.772 U/g creatinine)
in non-proliferative glomerulonephritis (Fig. 1). In con-
trast, thrombin was increased (8.259 6 6.590 U/g creati-
nine) in mesangial proliferative glomerulonephritis (P ,
0.0001) as compared with healthy controls and non-prolif-
erative glomerulonephritis. Antithrombin with heparin also
inhibited amidolytic activity in patients’ urine as potently as
hirudin (data not shown). Thrombin activity did not corre-
late with the degree of proteinuria or hematuria (data not
shown), indicating that the activity does not result from
leakage of thrombin produced in blood or from hemostasis
in bleeding glomeruli. Urinary thrombin activity was sup-
pressed by administration of Warfarin®.
The results demonstrate thrombin generation in mesan-
gial proliferative glomerulonephritis, probably in the glo-
merulus, and strongly support a hypothesis that thrombin
causes mesangial cell proliferation and disease progression.
Thrombin generation may result from enhanced expression
of tissue factor on monocytes or mesangial cells [5] in
inflamed glomeruli. Urinary thrombin activity could be a
useful reporter of thrombin generation in the glomerulus
and may be useful to determine an optimal dose of
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Fig. 1. Thrombin activity in the urine of normal controls (N 5 11), and
patients with non-proliferative glomerulonephritis (N 5 10), and mesan-
gial proliferative glomerulonephritis (N 5 9). Horizontal bars are the
mean values.
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anti-coagulant in the treatment of glomerulonephritis. Fur-
ther study will be needed to determine whether suppression
of thrombin activity in patients with increased urinary
thrombin activity could prevent proliferation of mesangial
cells and improve the prognosis of glomerulonephritis.
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